Suppr超能文献

C-myc、N-myc、N-ras和c-erb-B:在人甲状腺髓样癌及其衍生细胞系中缺乏扩增或重排。

C-myc, N-myc, N-ras, and c-erb-B: lack of amplification or rearrangement in human medullary thyroid carcinoma and a derivative cell line.

作者信息

Yang K P, Castillo S G, Nguyen C V, Hickey R C, Samaan N A

机构信息

Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030.

出版信息

Anticancer Res. 1990 Jan-Feb;10(1):189-92.

PMID:2185686
Abstract

We investigated the copy number and possible rearrangement of the four protooncogenes, c-myc, N-myc, N-ras, and c-erb-B, in DNA from seven untreated primary cancers or metastases of medullary thyroid carcinoma and an established human medullary thyroid carcinoma cell line, TT, using the Southern blotting technique. The purpose of this study was two-fold: 1) to examine whether protooncogene perturbations in medullary thyroid carcinoma could be considered as a prognostic marker; and 2) to determine whether the protooncogenes could have a possible role in medullary thyroid tumorigenesis. Neither amplification nor rearrangement of the protooncogenes was detectable in the DNA from any tumor samples or in the cell line. Our results suggest that DNA-evident amplification and rearrangement of the c-myc, N-myc, N-ras, and c-erb-B oncogenes may not be mechanisms through which these oncogenes become activated in this malignancy.

摘要

我们使用Southern印迹技术,研究了七种未经治疗的甲状腺髓样癌原发性癌症或转移灶以及已建立的人甲状腺髓样癌细胞系TT的DNA中四种原癌基因c-myc、N-myc、N-ras和c-erb-B的拷贝数及可能的重排情况。本研究的目的有两个:1)检查甲状腺髓样癌中原癌基因的扰动是否可被视为一种预后标志物;2)确定原癌基因在甲状腺髓样癌发生过程中是否可能发挥作用。在任何肿瘤样本的DNA或细胞系中均未检测到原癌基因的扩增或重排。我们的结果表明,c-myc、N-myc、N-ras和c-erb-B癌基因在DNA层面明显的扩增和重排可能不是这些癌基因在这种恶性肿瘤中被激活的机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验